Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Nastoupil on Questions Surrounding TGR1202 in Patients With CLL

August 21st 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the questions researchers are currently facing with TGR1202 in patients with chronic lymphocytic leukemia (CLL).

FDA Grants Brentuximab Vedotin Priority Review for CTCL

August 16th 2017

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma.

The Future of Treatment in Follicular Lymphoma

August 15th 2017

Novel Therapies in FL: Benefits and Challenges

August 15th 2017

Combination Therapy's Role in Follicular Lymphoma

August 15th 2017

Impact of Copanlisib in Follicular Lymphoma

August 15th 2017

Considering the Value of PI3 Kinase Inhibitors in FL

August 15th 2017

Addressing Unmet Needs in Salvage Therapy for FL

August 15th 2017

The Evolving Landscape of Salvage Therapy for FL

August 15th 2017

Choosing Therapy for Relapsed/Refractory FL

August 15th 2017

Continuing FL Treatment: Maintenance and Surveillance

August 15th 2017

Systemic Treatment for Newly Diagnosed FL

August 15th 2017

Triggers to Initiate Therapy for Follicular Lymphoma

August 15th 2017

Risk Stratifying Patients With Follicular Lymphoma

August 15th 2017

Follicular Lymphoma: Diagnosis and Staging

August 15th 2017

Dr. Nastoupil on Triplet of TGR1202, Ublituximab, and Ibrutinib in CLL

August 10th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Higher Bortezomib Doses Linked to Longer OS in MCL

August 10th 2017

Patients with newly diagnosed mantle cell lymphoma assigned to frontline chemotherapy had a survival advantage when they were able to receiver higher dose intensities of bortezomib (Velcade).

SF3B1 Mutation Associated With Poor Survival in CLL

August 8th 2017

Researchers in China have concluded that mutation of the SF3B1 gene is “significantly associated” with poorer progression-free survival and overall survival in patients with chronic lymphocytic leukemia.

MRD Associated With Poorer Survival Following ASCT in MCL

August 7th 2017

Long-term results from the Nordic MCL2 and MCL3 trials showed patients with mantle cell lymphoma who are positive for minimal residual disease following allogenic stem cell transplant had significantly shorter survival.

Dr. Andorsky on the MAGNIFY Trial in Follicular Lymphoma

August 3rd 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.